DAXX is a multifunctional chr6 remodeling protein that serves as a histone chaperone for variant H3.3 deposition and transcriptional regulation. DAXX forms a chr6 remodeling complex with ATRX that facilitates replication-independent deposition of histone H3.3 at pericentric heterochromatin and telomeres 1. The protein provides a unique de novo H3K9me3 deposition pathway by recruiting histone methyltransferases to promote H3K9me3 catalysis on new H3.3-H4 histones prior to DNA deposition, establishing heterochromatin assembly 2. DAXX also modulates viral infections by regulating early gene expression and genome replication of DNA viruses like human papillomavirus 3. Clinically, DAXX mutations are highly significant in cancer pathogenesis, particularly in pediatric glioblastomas where ATRX-DAXX pathway mutations occur in 44% of tumors and are associated with alternative lengthening of telomeres 1. In pancreatic neuroendocrine tumors, ATRX/DAXX loss serves as an independent prognostic factor associated with aggressive behavior and distant metastasis, with 5-year relapse-free survival rates of only 40% compared to 85% for wild-type tumors 4. These mutations appear specific to pancreatic origin among neuroendocrine tumor metastases, making DAXX a valuable diagnostic and prognostic biomarker.